secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harvard Apparatus Regenerative Technology, Inc. (HRGN)
CIK:        0001563665
Form:       8-K
Filed at:   2021-11-15T23:59:59+00:00
Accession:  0001104659-21-139180
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Biostage reports Q3 net loss of $0.8M; cash $2.0M, funds ops into Q2 2022
-------------------------------------------------------------------------

- Net loss for Q3 2021 was $0.8M ($0.8 per share) vs $0.7M ($0.07 per share) in Q3 2020.
- Nine-month 2021 net loss of $2.1M ($0.22 per share) vs $3.8M ($0.45 per share) in prior comparable period.
- Cash on-hand $2.0M as of Sep 30, 2021, up $1.5M from prior year.
- Proceeds of $2.6M from private placements of 1.3M shares and warrants in first nine months of 2021.
- Expects current cash to fund operating expenses and capex into Q2 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563665/000110465921139180/0001104659-21-139180-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563665/000110465921139180/tm2132943d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-21-139180

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer